EGFR and non-small cell lung carcinoma: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has become the first-line treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations (exon 19 deletion and exon 21 L858R).